Abstract | Urinary incontinence symptoms are highly prevalent among women, have a substantial effect on health-related quality of life and are associated with considerable personal and societal expenditure. Two main types are described: stress urinary incontinence, in which urine leaks in association with physical exertion, and urgency urinary incontinence, in which urine leaks in association with a sudden compelling desire to void. Women who experience both symptoms are considered as having mixed urinary incontinence. Research has revealed overlapping potential causes of incontinence, including dysfunction of the detrusor muscle or muscles of the pelvic floor, dysfunction of the neural controls of storage and voiding, and perturbation of the local environment within the bladder. A full diagnostic evaluation of urinary incontinence requires a medical history, physical examination, urinalysis, assessment of quality of life and, when initial treatments fail, invasive urodynamics. Interventions can include non-surgical options (such as lifestyle modifications, pelvic floor muscle training and drugs) and surgical options to support the urethra or increase bladder capacity. Future directions in research may increasingly target primary prevention through understanding of environmental and genetic risks for incontinence. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17042 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d . . Furthermore, women often delay or entirely defer presentation to their health care practitioners 15 ; even among women who receive a diagnosis, only a minority receive effective therapy 16, 17 . This Primer summarizes the current state of under standing of urinary incontinence in women, with a focus, in particular, on stress incontinence and urgency incon tinence. Both these areas have witnessed considerable innovations in practice over the past decade.
1
. The condition occurs in both sexes, but is much more frequent in women. Although some overlap in pathophysiology is evident between sexes, incontinence in men is often a consequence of prostatic enlargement or from damage to continence mechanisms during surgery or radiotherapy for prostate cancer. By contrast, incontinence in women is typically related to dysfunction of the bladder or pelvic floor muscles, with such dysfunction often arising during pregnancy or childbirth, or at the time of menopause. This Primer focuses on female urinary incontinence because of its higher prevalence and unique pathophysiology.
There are two main subtypes of urinary incontin ence: stress incontinence and urgency incontinence. According to the International Urogynecological Association (IUGA) and the International Continence Society (ICS) standard definition, stress incontinence is the complaint of urine leakage in association with coughing, sneezing or physical exertion, whereas urgency incontinence is the complaint of urine leak age associated with a sudden compelling desire to void that is difficult to defer 1 . These two subtypes are so common that they often coexist, as a combination of symptoms termed mixed incontinence. Most women with urgency incontinence also receive a diagnosis of overactive bladder syndrome
, of which urgency incontinence forms one possible component.
Rarer subtypes of incontinence in women include postural incontinence, which is the loss of urine with a change of body position (often when standing up or bending over); nocturnal enuresis, which is the leak age of urine during sleep; continuous incontinence, of which the common causes include vesical fistulae; and coital incontinence, the loss of urine during sexual intercourse 1 . The term 'functional incontinence' can be used to refer to incontinence in the setting of physical or cognitive impairment, such as hip fracture or dementia, that limits mobility or the ability to process information about bladder fullness 2 . Incontinence symptoms are highly prevalent, have a substantial impact on healthrelated quality of life 3 and are associated with huge personal 4 and societal 5, 6 expendi ture. All types of incontinence are more common with age and obesity [7] [8] [9] [10] , and so the public health burden of these conditions is likely to increase with current demographic trends. The burden on individuals and populations of these conditions 11 is quite disproportion ate to the attention they receive in the press, or the levels at which incontinence research is funded. Policy makers, medical professionals and the general public are largely unaware that urinary incontinence is a disease 12 , despite its International Classification of Diseases (ICD) classifi cation 13 . Part of this lack of awareness is rooted in the widespread misperception that incontinence represents a normal part of ageing, or is a natural consequence of childbirth 14 . Furthermore, women often delay or entirely defer presentation to their health care practitioners 15 ; even among women who receive a diagnosis, only a minority receive effective therapy 16, 17 . This Primer summarizes the current state of under standing of urinary incontinence in women, with a focus, in particular, on stress incontinence and urgency incon tinence. Both these areas have witnessed considerable innovations in practice over the past decade.
Epidemiology
Urinary incontinence is considered a stigmatizing con dition in most populations 18 , which contributes to low rates of presentation for care and creates a high risk for respondent bias in observational studies 19, 20 . The best prevalence estimates, therefore, come from general health surveys not focused on incontinence among representative samples using validated, symptombased questionnaires 21 . Such robust prevalence studies, using validated measures, exist for the United States and many devel oped European and Asian countries; populationlevel prevalence data for developing countries are less readily available. However, most early epidemiological studies did not differentiate between stress and urgency urin ary incontinence. The range of reported prevalence for urinary incontinence of any subtype in adult women is broad (5-72%), with studies converging on a prevalence of approximately 30% [22] [23] [24] [25] [26] [27] . This enormous variation between studies is observed both within and between countries. If true prevalence rates vary between countries, it is obscured by cultural differences in the perception of urinary incontinence and willingness to report urinary incontinence, as well as methodological differences 28 , including the wording of questionnaire items, the method of administration of questionnaires and -per haps most importantly -the differences in case defin itions used 25, 29 . These differences in case definitions relate to the time period over which symptoms are ascertained and whether symptom frequency, severity and bother are assessed. Indeed, studies specifically measuring severe urinary incontinence, defined as urine leakage several times per week, have a more consistent reported prevalence of 6-10% in Europe and the United States 26, 30 .
The association of urinary incontinence with age is well characterized. Across all available studies, the agespecific incidence is <2 per 1,000 personyears in women <40 years of age, but it increases with age 31 . For example, the EPINCONT study, a longitudinal study of women in Norway surveyed in 1995-1997 and again in [2006] [2007] [2008] , showed a 16% increase in the prevalence of urinary incontinence between the two time periods, with an incidence rate of 18.7% and a remission rate of 34.1% 26 . For the population as a whole, stress incontin ence is more common than either urgency or mixed incontinence in most studies [22] [23] [24] 26 . However, the preva lence of stress incontinence peaks in the fifth decade of life, and thereafter the prevalence of mixed and urgency incontinence continues to increase (FIG. 1) . Studies project that the prevalence of urinary incontinence and other pelvic floor disorders, such as pelvic organ prolapse and faecal incontinence, will increase as the global population ages 32 . It is estimated that the number of women in the United States with urinary incontinence will rise from 18.3 million in 2010 to 28.4 
million in 2050 (REF. 32).
Data regarding the association of urinary incontin ence with ethnicity are conflicting. Some studies have shown a higher prevalence of urinary incontinence in white women, whereas others have shown similar preva lence across ethnicities 19, 25, [33] [34] [35] . In several US stud ies, stress urinary incontinence is more common in white women than in AfricanAmerican or Asian American women 19, 34, 35 . Other factors associated with urinary incontinence in multiple, large, populationbased studies 25, [36] [37] [38] include parity 25, 26, 36 , obesity 25, 26, 36, 38 , previous hysterec tomy or pelvic surgery 25, 36, 38 , pulmonary dis ease 36, 38 , diabetes mellitus 22, 25, 26, 33, 37, 38 and nursing home admission or dementia 1, 3, 4 .
Mechanisms/pathophysiology
Bladder structure and function The bladder, urethra and urinary sphincters work in concert to store urine at low pressure and to void volun tarily at socially convenient or appropriate times. The detrusor muscle and internal urethral sphincter are predomin antly smooth muscle, whereas the external ure thral sphincter and pelvic floor muscles are predomin antly striated muscle. The bladder lumen is lined with epithelial cells (called urothelium) and the basement membrane (mucosal layer) that protect the underlying detrusor muscle from toxins contained in the urine and enable communication with neural cells that coordinate storage and voiding phases (FIG. 2) .
The sympathetic nervous system predominates during the storage phase and maintains continence through the paravertebral ganglia, the hypogastric nerves and hypo gastric plexus. The parasympathetic system coordin ates the voiding phase, through the sacral plexus and pelvic nerves (S2-S4) 39 . Afferent signals from the urothelium and bladder wall are transmitted through to the thala mus; the balance between storage and voiding is main tained by the central pontine micturition centre (FIG. 3) . The neurotransmitters responsible for execution of these commands are acetylcholine and noradrenaline.
Voiding up to 7 times per day in the waking hours is considered normal 1 , with a micturition volume of 250-300 ml per void (although the volume is typically higher with the first morning void). A healthy adult bladder has a limit of comfortable tolerance of approximately 500 ml, and can accommodate this relatively large volume of urine with little, if any, increase in intravesical pressure, owing to the viscoelastic compliance of the bladder. Although the anatomy of the bladder, urethra and urinary sphincters are well understood, the physiology underlying incontinence -particularly urgency incontinence -remains surpris ingly controversial. Several factors have been implicated in the mechanisms underlying stress and urgency incontin ence. These include damage to the endopelvic fascia and pelvic floor muscles that support the urethra, decreased function of the striated urinary sphincter, changes in the compliance and innervation of the detrusor muscle, changes in the urothelium, changes in urine composition and changes in the central nervous system.
Stress urinary incontinence
Two common, often overlapping, mechanisms for stress urinary incontinence have been described: urethral hyper mobility resulting from loss of support of the bladder neck and urethra (such that they move during peaks of abdom inal pressure), and weakness of the urinary sphincter itself. If the urinary sphincter mechanism is damaged, a specific subtype of stress urinary incontinence ensues, sometimes referred to as intrinsic sphincter deficiency. Weakness of the urinary sphincter can result from trauma, repeated urogynaecological surgeries, neuro logical disease, ageing or diseases leading to systemic muscu lar atrophy. Although all contemporary treatments are used for both subtypes of stress urinary incontinence, in general, treatments are more successful for patients with some degree of urethral hypermobility than for isolated weakness of the urinary sphincter 40 . The hammock hypothesis is widely accepted as the pathophysiological explanation of stress urinary incon tinence associated with urethral hypermobility 41 . The hypothesis states that the urethra is supported by the endopelvic fascia, which is the fibromuscular connective tissue of the vagina (FIG. 4) . The endopelvic fascia creates a 'hammock' against which the urethra is compressed dur ing rest and activity. This compression, combined with 'intrinsic' urethral sphincter pressure and mucosal coapta tion, effectively closes the urethral lumen and prevents the involuntary loss of urine even when the intravesical pressure increases. Damage to the arcus tendineus fasciae pelvis or paravaginal tissue as a result of excess loading from obesity, chronic cough, constipation, par turition or menopause can decrease the anatomical support of the bladder neck and the urethra. This loss of support results in hypermobility of the urethra, such that rather than being compressed at times of increased intraabdominal pressure, the urethra moves downward without being compressed -resulting in lower pressure in the urethra than in the bladder, with consequent urine leakage.
Urgency urinary incontinence
Unlike the physical changes associated with stress urinary incontinence, urgency urinary incontinence involves physiological perturbations to bladder function. There are three main aetiologies intrinsic to the bladder that lead to urgency incontinence: detrusor overactivity, poor detrusor compliance and bladder hypersensitivity.
Detrusor overactivity. Most current drugs for urgency incontinence block muscarinic receptors that mediate contraction within the detrusor muscle, or stimulate β3 receptors that promote relaxation. Many patients with urgency incontinence have measurable spontane ous uninhibited contractions of the detrusor muscle during bladder filling, called detrusor overactivity. These contractions can coincide with perceived urin ary urgency, and urgency incontinence can result if the pressure generated overcomes the resistance of the urinary sphincter.
Early hypotheses of the pathophysiology of detru sor overactivity were anatomically centred on the spine and parasympathetic motor supply to the bladderthe socalled neurogenic hypothesis 42 . Detrusor over activity is common after spinal injuries, with substantial spinal disease from multiple sclerosis or other lesions of the central nervous system. However, in the general Nature Reviews | Disease Primers population, neurogenic causes of detrusor overactivity are uncommonly identified 42 ; that is, detrusor over activity in most women is labelled as 'idiopathic' without finding a single pathophysiological cause.
Much research in the early 2000s focused instead on the detrusor muscle as the origin of detrusor over activity -the socalled myogenic hypothesis. This hypothesis is based on the recognition that both strips of bladder muscle and individual detrusor cells from patients with detrusor overactivity show heightened con tractile responses in vitro. Both myogenic and neuro genic mechanisms can coexist, so detrusor overactivity can be viewed as a multifactorial condition, akin to irritable bowel syndrome 43 . Although detrusor overactivity has been a major focus for research, it is only observed, at the time of urodynamics, in just over half of women pre senting with urgency incontinence, but may occur in at least half of elderly asymptomatic adults 44 .
Poor detrusor compliance. In low compliance, the bladder fails to stretch, which causes increased pressure, discomfort during filling and a limited capacity. This pattern is typical after pelvic radiotherapy, or can result from prolonged periods of catheterization.
Bladder hypersensitivity. Afferent sensory informa tion from the bladder has recently been established as a key factor in overactive bladder syndrome and, accord ingly, attention has focused on the sensory role of the urothelium in this condition (FIG. 5) . The urothelium is not merely a barrier, but is a responsive structure that is able to detect thermal, mechanical and chemical stim uli. Indeed, this is observed in both rodent and porcine models, with the mucosal layer of the bladder augment ing detrusor function, either through the release of vari ous neurotransmitters or through its own spontaneous electrical activity 45, 46 . With the recognition of the urothelium as a pivo tal mediator of bladder function, much attention has been concentrated on the role of urothelial inflamma tion and infection in the aetiology of overactive bladder syndrome. The balance of urinary microbiota 47 is now believed to substantially alter bladder sensation and, per haps, function. Historically, the bladder and urine have been considered as sterile, and urinary tract infection (UTI) in women was thought to result from ascend ing spread of uropathogenic organisms colonizing the vagina. However, the introduction of expanded quanti tative urine culture and 16S rRNA gene sequencing for bacterial identification has transformed our understand ing of the microbial ecology of the bladder. Sequencing of urine samples collected using specific techniques to avoid vaginal contaminants, from patients and healthy volun teers, has revealed a wide range of colonizing organisms that might be implicated in lower urinary tract dysfunc tion 48 . Evidence of exacerbation of lower urinary tract symptoms (LUTS) in association with both planktonic bacteria in the urine and urothelial colonization by bac teria has been reported [49] [50] [51] , but it remains unclear which species of bacteria may be responsible. When empty, the bladder has a pyramidal shape. As it fills and distends, the bladder balloons up above the pubic bones in an ovoid shape. The muscle of the bladder wall (the detrusor) consists of interdigitating fibres of smooth muscle, arranged in circular and longitudinal layers. These can stretch up to four times their resting length, so there is no increase in linear tension (or pressure) during normal bladder filling. The bladder and the ureters are both lined by a transitional epithelium, the urothelium. It contains flattened ('umbrella') cells and cuboidal cells, which also enable stretch as the bladder fills. The base of the bladder is a triagonal area, called the trigone. The ureters enter at the two superior corners of this triangle and the bladder neck lies at the inferior corner. The bladder neck is in continuity with the urethra, which, in women, is 2.5-4 cm long. The internal sphincter is formed of rings of smooth muscle at the bladder neck, whereas the external sphincter is formed by the muscles of the pelvic floor. Both sphincters help to close off the urethra to maintain continence. 
Myofibroblast
The vaginal microbiota can be classified into five communitystate types, of which four are dominated by different Lactobacillus species (L. iners, L. crispatus, L. gasseri and L. jensenii), whereas the fifth community is more diverse 52 . Most urinary bacterial communities are also dominated by lactobacilli 53 . Recent work explor ing the urinary microbiota have identified bacteria that would be considered as either commensal or pathogenic at other body sites 54 . As our understanding of the urin ary microbiota increases, we should expect to be able to differentiate common commensal organisms from bacterial colonizers that are likely to have a negative effect on urothelial function, and potentially lead to bladder hypersensitivity.
Diagnosis, screening and prevention
The presenting symptom of urinary incontinence is, by itself, not necessarily diagnostic of the subtype of urinary incontinence or its underlying cause. A comprehensive assessment is needed to determine the exacer bating factors, the effect on the woman's quality of life and her desire for treatment 55 . The typical diagnostic workup involves medical history, physical examin ation, urinaly sis (see below), assessment of postvoid residual volume and exclusion of conditions that require specialist referral (FIG. 6) . After these assessments, a provisional diagnosis of stress, urgency or mixed urinary incontinence can be made in the majority of patients 56 . Most women pres ent with a degree of mixed urinary incontinence, and . Afferent signals come from the urothelium and the bladder wall, through the pelvic nerves, and then go to the dorsal root ganglia and are projected to the periaqueductal grey, then to the posterior cingulate cortex (PCC). c | The main circuits for regulating desire to void include the insula and the lateral and medial prefrontal cortices, which feed back to the periaqueductal grey 181, 182 . The periaqueductal grey serves as a relay station for bladder information and activates the pontine micturition centre, which contracts the bladder and relaxes the urethral sphincter mechanism during voiding. d | The neurotransmitters responsible for the execution of these commands are acetylcholine and noradrenaline. establishing the predominant symptom can assist in directing the appropriate treatment. Depending on the severity of the individual components of their overall incontin ence, patients often benefit from initial treatment that is focused on urgency urinary incontinence.
Symptoms and risk factors
A comprehensive patient history includes the onset, duration and timing of urinary incontinence, and associ ated LUTS and voiding symptoms
, recognizing that the reported symptoms often relate to the patient's normal bladder function and expectations. Other risk factors or conditions that can exacerbate urinary incon tinence should also be assessed and include age, obstet ric history (parity and mode of delivery), gynaeco logical status (the presence of pelvic organ prolapse, defecatory dysfunction or anal incontinence, sexual dysfunction and urogenital syndrome of menopause), med ical status (the presence of a UTI, dementia, delirium, dia betes mellitus or diabetes insipidus, cardio respiratory disorders, chronic cough, obesity and obstructive sleep apnoea) and pharmacological status (the use of hormo nal replacement therapy, αadrenergic agonists and antagonists, calcium channel blockers, diuretics, lithium therapies, opioid analgesics, anti cholinergics and angiotensin converting enzyme inhibitors; BOX 3)
57 . Patients with mild cognitive impairment are 30% more likely to have urinary incontinence 58 . In addition, func tional and lifestyle factors, such as smoking status, mobility and frequency of heavy lifting, should be considered during assessment.
Some patients can present with a history that sug gests alternative lower urinary tract pathologies that also cause urinary incontinence, but require specialist referral. These symptoms include recurrent UTI; sterile pyuria (leukocytes in the urine); concurrent pelvic organ prolapse, bladder pain, haematuria and continuous leak age suggestive of fistula; urinary retention or obstruc tion; or neurological symptoms. Similarly, a history of uro gynaecological malignancy, pelvic irradiation, uro genital tract abnormalities or surgery should prompt a specialist referral 59 . In a patient who is frail, or those >65 years of age, a targeted history of reversible causes of urinary incon tinence includes an assessment of delirium, infection, pharmaceuticals, psychological morbidity, excess fluid intake, restricted mobility and stool impaction (the DIPPERS assessment 60 ) (FIG. 6) .
Physical examination
Physical examination should include a functional assess ment observing the mental status and mobility as well as body mass index of the patient. Abdominal examin ation should assess for pelvic masses, a palpable bladder and costovertebral angle tenderness. The urogenital examin ation might reveal vaginal atrophy and incontinence associated dermatitis (that is, damage to the skin with exposure to urine).
A positive cough stress test (whereby observed ure thral leakage is provoked by a series of forceful coughs in the supine or standing position with a comfortably full (~300 ml) bladder volume) has a high sensitivity and specificity for diagnosing stress urinary incontin ence 61 . After emptying the bladder, a positive supine empty stress test can be suggestive of intrinsic sphinc ter deficiency 62 , but invasive urodynamic studies are required to confirm the diagnosis 63 . The findings should be related back to the patient's predominant reported type of urinary incontinence to ensure prioritization of management for the symptom of most bother.
Evidence of pelvic organ prolapse should be observed during a Valsalva manoeuvre (that is, forced attempted exhalation against a closed airway) over ≥6 seconds 64 in whichever position maximum protrusion is best demon strated (supine, left lateral or standing). The validated staging of pelvic organ prolapse is described by Pelvic Organ Prolapse Quantification (POPQ) 65 , but a simpli fied description (SPOPQ) has also been validated for use in clinical practice 66 , in which staging is based on assessment after the bladder is emptied. This staging system only defines anatomical descent and does not define the normal range, with up to 50% of women having stage 2 descent. Only a weaktomoderate corre lation between anatomical descent and urinary symp toms has been shown, with common prolapse symptoms being a vaginal bulge, sensation of heaviness or difficulty in voiding 67 . For women with stage 2-4 pelvic organ prolapse, the anatomical distortion may kink the urethra, some times resulting in a falsenegative cough stress test. Thus, reducing the prolapse digitally without distorting the bladder neck while performing a cough stress test might be of value. However, limited evidence has been reported on how to optimally reduce urethral kinking for the test 68 . The relationship between urethral mobility and stress urinary incontinence has been assessed using a range of techniques, including the POPQ point Aa descent 69 , urethral Qtip 70 , vaginal cotton swab 71 , visual evalu ation 72 , ultrasonography 72 and lateral chain urethro cysto graphy 73 . However, none of these is recommended and there is no consensus definition for clinically rele vant urethral hypermobility. The advantage of hyper mobility assessment lies in finding the absence of urethral descent, which is associated with a twofold higher rate of surgical failure 74 . A digital examination palpating the pelvic floor for muscle tone, contraction technique and strength is advised. Standardized terminology has been developed to describe pelvic floor function, but no standardized method or normative value for measurement or classifi cation is available 75 . Other abnormalities such as ure thral diverticulae (outpouching of the urethral mucosa, which creates a midline anterior wall cystic mass) and pelvic masses can also be identified when assessing for pelvic organ prolapse. Finally, a speculum examination can assist in assess ing each vaginal compartment as well as assessing for any extraurethral loss of urine that may suggest a fis tula. Any bowel dysfunction or neurological symptoms should prompt a rectal examination assessing for tone and sphincter squeeze. In addition, bowel dysfunction should prompt a general neurological examination, including testing of the S2-S4 nerve distribution 63 .
Urological tests
Diagnosis might also require objective and semi objective measures, such as voiding diaries, pad tests, urinalysis and urodynamic tests.
Urinalysis. Urinalysis using a colorimetric reagent test strip evaluates urine for a range of chemical parameters including pH, protein, glucose, ketones, occult blood, bilirubin, urobilinogen, nitrite, leukocyte esterase and specific gravity. Urinalysis is recommended as a screen ing tool for UTIs and other associated conditions in the assessment of urinary incontinence 76 . Indeed, the criteria for diagnosing overactive bladder syndrome and detrusor overactivity require the exclusion of UTIs. Urine reagent dipsticks have a low sensitivity and high specificity for the exclusion and identification of UTIs 77, 78 , respectively.
Formal microscopy, culture and antibiotic sensitivity (MCS) analyses of a cleancatch urine specimen or cath eter urine specimen are recommended 79 in women who have symptoms of UTI or have a positive dipstick 63 . The microbiological criteria for UTI are defined as bacteriuria of >100,000 colonyforming units (CFU) per ml on voided specimen or >1,000 CFU per ml on catheterized specimen with pyuria (defined as >10 white blood cells per ml). This diagnostic threshold is impor tant given the association between lowCFU bacteriuria count (<1,000 CFU per ml), urinary incontinence 50 and refractory LUTS. In those with a history of recurrent UTIs, requesting the results of the previous microscopy, culture and antibiotic sensitivity analyses can assist in confirming the diagnosis, determining the correct treat ment based on sensitivities and determining whether the UTIs are recurrent or persistent 1 . In addition to screen ing for infection, urine dipsticks detect the presence of blood, glucose and protein, and have a role in screening for malignancy, diabetes mellitus and renal impairment.
Elderly patients have a high prevalence of asympto matic bacteriuria. Thus, care should be taken in inter preting urinalysis findings in relation to the symptoms to avoid overuse of antibiotics that might be of little benefit or even harm 80 . The revised McGreer criteria Figure 6 | Diagnostic work-up of women with urinary incontinence. The initial management of urinary incontinence includes a detailed history and physical examination to identify potential reversible causes of symptoms, followed by urinalysis with microscopy, voiding diary, assessment of post-void residual volume and cough stress test to assist with diagnosis and initial management. In cases of advanced pelvic organ prolapse, prior pelvic surgery, haematuria or urinary retention, patients may be referred to a urologist or urogynaecologist. UTI, urinary tract infection.
Refer to a specialist urologist or urogynaecologist if there is:
• Post-void residual volume assessment. The postvoid residual (PVR) volume is determined by measuring the volume remaining in the bladder immediately after voiding; it is a measure of the completeness of bladder empty ing. Thus, it is recommended when evaluating those with voiding symptoms, symptomatic pelvic organ prolapse or palpable bladder overdistension 82 . Measuring the PVR volume can be achieved using ultrasonography, with either a bladder scanner or formal renal tract imag ing, or an in-out catheter. The technique has accept able sensitiv ity and specificity and, importantly, greater patient acceptability and lower adverse outcomes than the gold standard of catheterization 76, 83 . An increased PVR volume when assessed immediately postvoid is defined as >30 ml, but may be up to 100 ml if assessed 10 minutes postvoid and depends on the method of measurement 1 . However, there is wide variation in what clinicians consider to be a clinically significant PVR vol ume. In those with a PVR volume of ≥100 ml, there may be benefit in repeating the measurement in the event of a falsepositive diagnosis of increased PVR volume 84 . Although large and persistent PVR volumes might be related to UTIs, there is little evidence for the effect of increased PVR volume on urinary incontinence and storage symptoms. However, evidence of voiding dysfunction is still important to determine because it can alter the choice of urinary incontinence treatment options, as some treatments can further impair void ing (for example, intradetrusor onabotulinumtoxinA (commonly known as Botox (Allergan)) and surgical procedures for stress urinary incontinence).
Voiding diaries.
As an objective measure of mean voided volume, frequency and urinary incontinence frequency, 3 to 7day voiding diaries are widely used as a reliable tool that is sensitive to small changes 83 . Three types of urin ary diary can be used: a micturition chart to record the timing of each void, a frequency-volume diary to record the volume voided with the time and a bladder diary to record additional information on urinary incontinence episodes, pad usage, fluid intake, fluid type and sensation of urgency 1 . In addition, the 24hour urine production can provide an assessment of daytime and nocturnal poly uria, which may be particularly useful in older women with nocturia
. Some women might be unable to complete the bladder diary for functional reasons, such as cognitive impairment. The value of the diary may also be limited in those with either very severe or unconscious urinary incontinence, whereby leakage can be difficult to accurately record. Under these circumstances, other methods, such as pad tests, are of more value.
Pad testing. Pad testing uses an absorbent perineal pad worn by the patient to detect the presence of urinary incontinence and to measure the volume lost, and can be a useful correlate with symptoms 83 . The pad is worn for up to 24 hours while conducting a range of normal activities designed to replicate the usual provocations of urinary incontinence, such as walking and exercis ing 1 . Some increase in pad weight can occur through 85, 86 . Although abnormalities observed can be associated with urinary incontinence, such imaging is not predictive or diagnostic of the cause of the incontin ence 87, 88 . Ultrasonography might have a role in con firming the findings of the patient history and clin ical examination, assessing postoperative complications 89 or as a means of providing biofeedback to help women to identify effective pelvic floor contraction during pelvic floor muscle training (PFMT) 90 
.
Urodynamic studies. Urodynamic studies constitute a series of investigations assessing lower urinary tract function that include uroflowmetry, voiding cysto metry, filling cystometry, urethral function and provocative manoeuvres to demonstrate urinary incontinence (FIG. 7) . Auxiliary tests using fluoroscopy or ambulatory equip ment might also be of value 91 . Depending on the clinical or research context, such studies can provide a range of information that includes identification of factors that contribute to LUTS and their relative importance, assess ment of other aspects of lower urinary tract function, prediction of the consequences of lower urinary tract dysfunction on the upper tracts (particularly in patients with neurogenic causes of incontinence), prediction of the consequences and outcomes of treatment, investiga tion of reasons for treatment failure and investigation of the effects of interventions 55 . When used in clinical practice, the urodynamic studies should be of suitable technical quality 92 and the process should replicate the patient's symptoms to provide results relevant to the clinical problem 83 . To achieve the quality required, the studies should be conducted in a standardized manner with parameters reported according to published reference ranges 92 . In the research setting, standardization enables com parison of study cohorts and outcomes. In the clinical setting, standardization enables the clinician to prov ide evidence based recommendations relevant to the patient's clinical problem.
Conducting a urodynamic study is associated with risks that include procedurerelated discomfort and postprocedure transient dysuria (painful urination; 47% of patients), haematuria (14%), bacteriuria (12%) and symptomatic UTI (28%), with no significant reduction in UTI when prophylactic antibiotics are given 93 . For those classified as having overactive bladder syndrome, only around half demonstrate detrusor overactivity, and only onequarter of those with uninhibited detru sor contractions have overactive bladder symptoms 94 . Accordingly, urodynamic studies are not recommended before nonsurgical management of uncomplicated stress, urgency or mixed urinary incontinence 76, 82, 83 . Similarly, in patients with symptomatically predominant, demonstrable stress urinary incontinence, no pelvic organ prolapse and a PVR volume of <150 ml, treat ment outcomes are not improved in those undergoing urodynamic studies before primary surgical treatment 95 , even when the urodynamic results are discordant with the symptoms of the patient 96 . Given these limitations, urodynamic studies are of value if the incontinence diagnosis remains uncer tain after the initial assessment, when symptoms do not correlate with physical findings or after failed pre vious treatment 55, 82 . Similarly, urodynamic studies should be performed in patients who are considered for invasive, morbid or irreversible overactive bladder or detrusor overactivity treatments, and in those with neurogenic or obstructive voiding conditions. In those with urinary incontinence and an associated neuro logical condition (for example, neurogenic urinary incontin ence), the addition of radiological imaging at 
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• Can cause oedema, which can lead to nocturnal polyuria causing nocturia and nocturnal enuresis the time of invasive urodynamics for the detection of urinary tract anomalies and vesicoureteric reflux is regarded as the goldstandard investigation 97 . Other specialist uro neurophysiological tests include electro myography to assess muscular responses to bladder stimuli, pudendal nerve conduction testing and reflex latency measurements 98 .
Screening and prevention
Several populations might benefit from proactive screening for symptoms of urinary incontinence, including older women who are frail, for whom there is a high prevalence of urinary incontinence and related morbidity 55 , including falls and fractures. Other high risk groups include pregnant patients, for whom urinary incontinence preventive measures such as fluid manage ment, PFMT and bladder retraining can be offered. Women presenting with other pelvic floor disorders (such as pelvic organ prolapse) might also benefit from screening, as the prevalence of urinary incontinence in this population is >60% 98 .
Management
The management of urinary incontinence in adult women is an iterative process. For some affected women, urinary incontinence causes sufficient bother and intru sion to warrant consideration of treatment. The options range from lifestyle modification to moreinvasive sur gical interventions 99 . Otherwise healthy women might prioritize resolution of their urinary incontinence by actively engaging in pelvic floor rehabilitation, lifestyle changes (including fluid optimization), pharmaco logical treatment or surgery to resolve persistent symp toms. Alternatively, women with other serious health conditions might consider their urinary incontinence as a chronic condition, with the emphasis on decreas ing symptom impact rather than complete resolution. This spectrum of engagement in treatment of urinary incontin ence changes over a woman's lifetime and reflects her changing health priorities and preferences. Thus, the goals might vary between the ideal of independent con tinence with minimal symptoms and the compromise of dependent continence (in which the patient remains dry through regular toileting) or contained incontinence (in which the patient remains dry through the use of aids) 100 . Goals and preferences are likely to change with time and should be periodically reconsidered 101, 102 .
Role of the multidisciplinary team
Multidisciplinary care for women with urinary incontin ence is regarded as important 76 . Such disciplines include physiotherapy, specialist nursing, occupational therapy, gynaecology, urology and geriatrics, with each provid ing a different service within their scope of practice. Although little evidence supports the comparative effectiveness of any discipline in particular, the data on outcomes of patients treated with multidisciplinary expertise are promising 103 .
Non-surgical interventions
Women with mixed urinary incontinence often experi ence symptom reduction as they embark on behavioural Invasive (catheterized) pressure measurements during urodynamic studies include intravesical pressure (using a probe in the bladder) and abdominal pressure (using a probe in the rectum as shown or in the vagina (not shown)). In addition, electromyography (EMG) can be used to evaluate the activity of the muscles of the pelvic floor. During the test, the bladder is filled and then the patient is asked to void, with continuous pressure monitoring during filling and emptying. In women with urgency incontinence, findings can include uninhibited contraction of the detrusor muscle during filling (detrusor overactivity) or a gradual uncomfortable rise in pressure during filling (low compliance). A formal diagnosis of stress incontinence is made by observation of leakage with coughing or exertion in the absence of detrusor contraction.
changes that may include weight loss, timed voiding or bladder retraining and fluid optimization 104 . These inter ventions can be initiated without exhaustive diagnostic workup, unless signs or symptoms suggest a need for specialist referral. Women with urinary incontinence vary in their willingness and ability to engage in these firstline interventions; however, for women who are able to work closely with their clinical team, signifi cant improvements in symptoms can be achieved 105 . Patients with mixed urinary incontinence benefit from interventions that are designed to optimize fluid intake, medication use and pelvic muscle function 106 .
Fluid optimization. Important clues to potential manage ment strategies are often detected during evalu ation and the initial diagnosis. For example, if a voiding diary reveals a fluid intake pattern that exacerbates symptoms -such as excessive total fluid intake, large fluid intake before sleep and a pattern of infrequent but large fluid bolus intake -changes might be warranted. Similarly, the intake of caffeinated, alcoholic and carbon ated drinks can be temporarily modified to determine whether incontinence symptoms improve. Some med ications (BOX 3) are associated with an increase in incontin ence symptoms; in such cases, mindful adjustments to fluid intake and optimizing medication timing can facilitate symptom reduction and decrease withdrawal from social interactions.
Weight loss. Weight reduction in women who are over weight or obese can substantially improve symptoms and associated bother 107, 108 . Clinicians and patients alike are aware of the challenge this poses for most individ uals who are overweight. However, one study showed that, for those enrolled in a weight loss programme and losing at least 3-5% of their baseline weight, a 47% reduction in stress incontinence episodes 109 was achieved, with concomitant reduction in urge incontinence epi sodes. Similarly dramatic improvements have been demonstrated with bariatric surgery and other weight loss modalities 110 .
PFMT. PFMT aims to improve pelvic floor muscle func tion. The strongest evidence of benefit is for supervised PFMT in women with stress incontinence, with less effi cacy in those with urgency incontinence 111 . Emerging evidence supports unsupervised delivery of PFMT 112 , which could be costeffectively delivered through e training 113 . Women are taught to consciously contract their pelvic floor muscles before and during any increase in abdominal pressure, such as coughing, to avert leak age, and simultaneously to build up the support of the pelvic floor through regular muscle strength training 114 . These exercises are often supplemented by bladder retraining advice (systematically increasing voiding interval), techniques to avert urinary urgency 115 and to avoid immin ent stress induced leakage 116 . In those who are unable to contract the pelvic floor, biofeedback tech niques might be useful 90 . Although shortterm efficacy is good, with no harmful effects, evidence of longterm benefit is lacking [117] [118] [119] .
Incontinence pessaries and intravaginal devices.
Women seeking further treatment for stress urinary incontinence who wish to avoid or defer surgery, and are unable to adhere to behavioural therapy, can use vaginal continence pessaries 120 , which aim to compress the ure thra. These treatments show the greatest benefit in those with severe stress urinary incontinence 121 . New options are becoming available, including tamponlike devices licensed for overthecounter sale, but the effectiveness of these devices is yet to be established.
Continence aids and products. Counselling and guid ance about the appropriate use of incontinence aids and pads are important for enhancing quality of life and reducing the stigma of incontinence. The range of prod ucts includes mobility aids, accessible commodes and containment products, such as absorbent pads or cathe ters. When choosing the optimal product, many things must be considered. Nurse continence advisers are best placed to counsel patients and provide access to these products, although independent webbased resources (such as https://www.continenceproductadvisor.org/) are also available for patients and health care providers.
Medical interventions
Should firstline lifestyle, behavioural and physical thera pies be ineffective in treating urinary incontinence, a range of pharmacological agents are available, depending on the specific incontinence symptoms. As for any medication, the woman's coexisting conditions, use of other existing medication and risk of adverse effects should be consid ered before prescribing. For many of these medications, the benefits may not be observed for several weeks, so it is important to reliably assess baseline symptoms to enable comparison with the treatment effects. Women should also be cautioned about this delay in response.
Vaginal oestrogen. Lowdose vaginal oestrogen should be offered when appropriate to women with urogenital atrophic changes, to promote improved blood supply and decrease LUTS. A metaanalysis of 14 randomized con trolled trials (RCTs) in postmenopausal women showed that vaginal oestrogen was associated with improved incontinence 122 . Systemic hormone replacement ther apy has been associated with worsening incontinence outcomes 123 , particularly for combination oestrogen and progesterone. The reasons for this harmful effect remain unclear.
Anticholinergic drugs for urgency incontinence.
Anticholinergic drugs (also known as antimuscarinics) are often used in primary care alongside behavioural and lifestyle modifications as part of firstline ther apy. Anticholinergic drugs act directly on the detrusor muscle, which leads to reductions in urgency urinary incontinence, with concomitant improvements in urinary urgency, voiding frequency and, to a lesser extent, noc turia 124, 125 
. Improvement in these key bothersome symptoms is associated with moderate gains in quality of life 126 . The different licensed anticholinergics offer a range of dosing schedules and, in the case of oxybutynin, are available as either oral or topical formulations, with the latter preparation also available over the counter for women in the United States. All available drugs cause typical cholinergic adverse effects, including dry mouth, constipation, blurred vision, somnolence and confu sion [127] [128] [129] (TABLE 1) . Owing to adverse effects, costs and inconvenience, adherence to treatment is often poor [130] [131] [132] . Oxybutynin was the first drug with level 1 evidence of efficacy and is sometimes still recommended as a first choice, despite its poor adverseeffect profile 76 . All newer anticholinergic medications for overactive bladder syndrome have been compared in RCTs against both placebo and oxybutynin as a condition of licensing. The overall effect of this class of drugs is very modest, with few longterm treatment responders 133 . Very few headtohead studies of contemporary anticholinergic medications have been conducted, and when direct com parisons have been made, the evidence of differential effi cacy is limited 134 . The longterm effects of anticholinergic incontin ence medications (cholinergic load) on cogni tive function and incident dementia are emerging 135 , particularly in older patients and in those already using other medications with anticholinergic effects. In these patients, alternative medications are recommended 83 . β 3 -adrenergic agonists for urgency incontinence. Mirabegron is a β 3 adrenergic receptor agonist that acts directly on the detrusor muscle. In licensing trials, mirabegron was tested against placebo and tolterodine (an antimuscarinic), and subsequent postmarketing trials tested it against, and in combination with, sev eral anticholinergics 136, 137 . Metaanalyses have shown similar efficacy to available anticholinergic drugs, but with a much reduced incidence of dry mouth 138, 139 , and lower efficacy than intravesical onabotulinumtoxinA 140 . Mirabegron has the potential to exacerbate hyperten sion 131 , but is otherwise well tolerated compared with most anticholinergics, with good persistence 141 . However, for most patients, symptom improvement is quite mod est. Mirabegron is best used in patients for whom there is a contraindication to, or risk of cognitive or other adverse effects from, anticholinergics.
Serotonin-noradrenaline reuptake inhibitors for stress incontinence. Duloxetine is a serotonin-noradrenaline reuptake inhibitor (SNRI) that is widely used in depres sion. SNRIs are proposed to increase the levels of sero tonin and noradrenaline at the presynaptic neuron in the nucleus of Onuf (FIG. 3) of the sacral spinal cord by inhib iting reuptake and increasing striated urethral sphincter activity and urethral pressures 142 . Duloxetine was licensed for the treatment of stress incontinence in the European Union after RCTs initially suggested efficacy 143 , but licensing for the indication of stress incontinence failed in the United States owing to concerns of adverse events, including nausea and suicidal ideation. Accordingly, the drug is not recommended as firstline therapy 59, 76 , and persistence of use for the indication of incontinence is poor 144 ; thus it is not commonly used.
Invasive interventions
Stress incontinence surgery. Although conservative meas ures should be tried first 59 , surgery to treat stress urinary incontinence is highly effective in reducing symptoms (FIG. 8) . Women with mixed incontinence are candidates for surgery but are likely to need adjunctive treatment for their urgency incontinence. Synthetic midurethral sling placement is currently the firstline surgical procedure, with a cure rate of >80% 145 and low morbidity rate 145 . Both the retropubic and transobturator techniques are based on a strip of polypropylene mesh 146 . Complications of vaginal mesh surgery have become a common cause of litigation, and although the risk of complications is lower for midurethral slings than for mesh for prolapse, these procedures need meticulous documentation of the con sent process. For women and/or clinicians seeking non meshbased procedures, a fascial sling or retropubic urethropexy are viable options 147 , with similar overall efficacy 148 and similar complication rates, but additional risks 149 . Surgical risks include bleeding, infection, voiding dysfunction, visceral injury, pain and anaesthetic con cerns. Persistent stress urinary incontinence after an initial surgery should prompt an updated diagnostic evaluation; subsequent stress incontinence surgery is a possibility for women whose initial surgery was not successful and whose diagnosis remains stress urinary incontinence, but are generally less successful than the primary procedure 150 . A small number of women develop de novo urgency urinary incontinence symptoms following stress incontin ence surgery 145 , which can be associated with position, tension or the inadvertent introduction of surgical material within the bladder or urethra. Once such com plications are excluded, traditional treatment for urgency urinary incontinence can be initiated. More commonly, women with mixed urinary incontinence undergo surgery to resolve the stress urinary incontinence component of their condition. Although some of these women experi ence resolution of their urgency urinary incontinence, some have ongoing, bothersome symptoms 151 . Treatments aimed at reducing urgency urinary incontinence symp toms that were not effective before surgery should be tried again, especially if after the surgery the symptoms of stress urinary incontinence are reduced or resolved. Clinician encouragement and management of expectations are especially important during this postsurgical treatment window, as women might feel dejected that incontinence symptoms are present despite complete or nearcomplete resolution of stress urinary incontinence symptoms.
Neuromodulation. Neuromodulation uses direct elec trical stimulation to modify bladder sensation and con traction. Various forms of neuromodulation are also available and might be preferred by women with urgency incontinence who wish to avoid daily oral medication. Implantable neurostimulation uses a programmable stimulator placed subcutaneously that delivers low amplitude electrical stimulation to the sacral plexus via a lead through the S3 foramen. It has high initial costs and high risks of revision surgery 152 . By contrast, percu taneous tibial nerve stimulation is a lessinvasive, office based technique that offers a reasonable rate of symptom response 153, 154 . Neither type of neurostimulation is uni formly effective, and careful patient selection is manda tory for both. These therapies should be considered third line after failure of firstline and secondline therapies.
Intravesical onabotulinumtoxinA injections. Intravesical injection of onabotulinumtoxinA is essentially a form of 'chemical' neuromodulation that acts at the detrusor presynaptic neuromuscular junction. It has an efficacy similar to oral medication for urgency urinary incontin ence but without the need for a daily medication 155, 156 . The administration procedure is usually performed under a general anaesthetic, and is accordingly reserved as a thirdline treatment. Treatment injections need to be repeated when symptoms recur (approximately 9-12 months). The risks include transient urinary reten tion and UTIs, which may require patients to learn to pass a urinary catheter to drain off any residual urine. Despite these risks, the procedure is popular with patients and physicians and offers a real hope of cure for patients with even the most recalcitrant symptoms.
Quality of life
During a woman's lifetime, various health conditions can challenge bladder function. Urinary incontinence symptoms can worsen or improve, and the desire for A woman who has experienced prior success with noninvasive treatments might initiate selfcare or request referral for simple manage ment. A woman who underwent successful sur gery 15 years ago may now be experiencing a change in bladder symptoms, despite efforts at regular pelvic floor muscle exercises. Those who have lived with urinary incontinence as a chronic condition might feel nihilis tic about management recommendations; instead, goals might relate to avoidance of certain threshold events, such as avoiding placement in a nursing home because of bladder control concerns.
All subtypes of urinary incontinence are highly bother some, and management should begin by assessing the patient's willingness to engage in treatment, determin ing the level of treatment desired and discussing current evidence and recommendations for specific treatment, including benefits, alternatives, risks and complications. Furthermore, assessment of quality of life has become an integral part of determining the effect of urinary incontinence on the individual and assessing the benefit of treatments.
Patientreported outcomes (PROs) provide an objec tive assessment of subjective symptoms that may assist in identifying the primary symptom to be treated, choos ing the type of treatment and determining treatment goals and success. In the research setting, PROs provide a standardized set of data to be collected and outcome measures. Although these tools are widely used and recom mended, no evidence suggests that the use of PROs alone improves treatment outcomes 83 . Several PRO tools have been developed (TABLE 2) , but no single questionnaire has been valid ated to measure all incontinenceassociated outcomes 83 and no single questionnaire has been univer sally adopted for the assessment of quality of life 157 . When considering a questionnaire, clinicians and researchers should assess its compatibility with their outcome objec tives, suitability in the patient group and consider the time and effort burden of lengthy surveys on patients.
The severity of urinary incontinence has been repor ted as a risk factor for poor quality of life 158 and has a negative effect on many dimensions of quality of life, mental health and social activities. Although not life threatening, urinary incontinence can certainly prove to be life changing 159 . In one Austrian study, 65.7% of women stated that their quality of life was affected by continence status 160 . In another populationbased longi tudinal study, urinary incontinence predicted the onset of psychological distress among communitydwelling adults (≥50 years of age), especially when associated with conditionspecific functional loss, and this distress can prompt the individual to avoid social or religious gather ings, travel, physical activities and other everyday activi ties such as shopping 161 . Incontinence symptoms have also been associated with sexual dysfunction 162 and neg ative effects on marital relationships 163 or partnerships. Women with urgency urinary incontinence are generally more bothered than those with stress urinary incontin ence, because the leakage is unexpected, sudden and often of large volume. These women show worse scores on quality of life and depression scales, poorer quality of sleep, worse sexual function and lower productivity than matched controls 164 . Urinary incontinence also has negative effects on the psychological burden of family caregivers 165 . The mean total score from the Zarit Burden Interview, one of the most widely used tools to measure caregiver burden, was significantly higher among caregivers of patients who were incontinent than among those of patients who were continent. Male partners of women with urinary incontin ence also report lower sexual function and sexual satisfaction 166 . Overall, female urinary incontinence and urgency negatively affect sexual function in almost 50% of affected women and in 20% of their partners 167 . Finally, understanding the crucial link between urinary incontinence and quality of life is pivotal to maximizing the efficacy of routine screening and early intervention 168 . Given the broad extent of the reduction in quality of life from urinary incontinence, measurement of quality of life should also be considered in the design of almost all clinical studies of urinary incontinence interventions.
Outlook
Advances in incontinence research suggest that we might be at the cusp of a revolution in several research areas, especially in understanding continence physiology and in primary prevention. More than 130 years of research into bladder and urethral sphincter dysfunction 169 have revealed overlapping underlying causes of bladder dys function, including the myogenic, neurogenic and uro theliogenic hypotheses 42 . However, the development of new drugs has been hampered by a historical focus on detrusor overactivity as a supposed unifying 'cause' of urin ary urgency and urgency incontinence. The relation ship between urgency and detrusor overactivity is remark ably complex -whether detrusor overactivity is a cause or a consequence of urgency incontinence is itself unclear.
Despite a lack of evidence linking detrusor overactivity to urgency incontinence, it has often also been used as a surrogate end point in clinical trials of interventions of all modalities. Many current treatment options, including anticholinergic medicines and sacral neuromodulation, reduce detrusor overactivity measurably. However, the presence of detrusor overactivity at baseline has been shown to be a poor predictive factor of treatment out come for a wide variety of incontinence interventions 44 . There is considerable interest in new bio chemical and imaging biomarkers that might replace detrusor over activity as an objective clinical end point; however, none has progressed to widespread adoption in clinical practice. The most widely tested urinary marker, nerve growth factor, has demonstrated problems with specific ity and reproducibility 170 . The most widely investigated imaging marker, bladder wall thickness, also failed to demonstrate prognostic value when tested in a large trial of implementation 171 . At the present time, the best clinical end points are subjective rather than objective: symptom severity and qualityoflife impact as reported by patients on validated instruments.
Recent genomewide association studies have attemp ted to shed light on the molecular pathogenesis of incontinence. The discovery of new genetic risk vari ants for incontinence 172, 173 and the interrogation of those variants as known causes of objectively measured bladder dysfunction might provide striking insight into the actual variation in human bladder physiology associated with incontinence. Accordingly, we might identify new sub types of urgency incontinence at which we can direct targeted care.
In addition to the expanding understanding of bladder physiology, primary prevention of incontinence is a growing area of interest. For example, our increas ing understanding of the microbiota of the urinary tract might lead to effective interventions to correct urinary dysbiosis or to modify the resident microbial flora. Topical vaginal oestrogens are already used for postmenopausal women with incontinence, and, in part, act to normal ize the vaginal flora 174 . Four currently available bladder vaccines (Urovac (Solco Basel) includes heatkilled uro pathogens as an intramuscular injection; OM89/ UroVaxom (Vifor Pharma), an oral preparation of bac terial lysates; and Urvakol (Institute of Microbiology, Prague, Czech Republic) and Urostim (National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria), which are wholecell inactivated uropathogens in an oral tablet) target Escherichia coli and other uropathogens, and are marketed for the prevention of recurrent UTI with modest evidence of efficacy 175 . Novel vaccine approaches are currently emerging. It seems plausible that similar targeted interventions to modify the vaginal or bladder microbiota might be useful for incontinence.
Successful primary prevention of incontinence will depend on the accurate identification of women at high risk. Cohort studies suggest that persistent childhood incontinence strongly predicts adult symptoms 176, 177 . Although it is unclear whether this predisposition to incontinence is predominantly genetic or environmental, the recognition of predisposition offers an opportunity to intervene at appropriate times. In parous women, vaginal delivery is a key modifiable risk factor for adult stress urin ary incontinence, with traumatic delivery unmasking incontinence in predisposed women 177 .
Ongoing studies, such as URCHOICE 178 , aim to test the acceptability of providing pregnant women with tailored risk estimates for incontinence, and will provide valuable insights into the efficacy of riskreducing ante natal and intrapartum interventions that target highrisk women. Such data would provide important informa tion for obstetricians, who must be selective in the use of prelabour caesarian section, with vaginal birth being only one contributing factor for incontinence 179 . The risks and benefits of elective caesarian should be carefully weighed given the substantial risks as a primary procedure and for future deliveries, including maternal mortality, stillbirth, placenta praevia, uterine rupture, neonatal respiratory morbidity, hysterectomy, and bladder and bowel injuries. In the absence of interventional studies, new research is needed to understand whether genetic information can be additionally used to successfully identify women who would benefit from caesarian delivery, and whether such a strategy would have any sustained benefit to incontinence and any overall impact on healthrelated quality of life.
